This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Ambicion Co., Ltd., Riken Corporation. Active years: 2023.
Company Filing History:
1 out of 1 
1 out of 886 
Years Active: 2023
Title: Keigo Hanada: Innovator in NKT Cell Activation Technology
Introduction
Keigo Hanada is a prominent inventor based in Tokyo, Japan. He is known for his significant contributions to the field of immunology, particularly in the activation of NKT cells. His innovative work has the potential to advance therapeutic strategies in various medical applications.
Latest Patents
Hanada holds a patent for a technology that focuses on the efficient activation of NKT cells. The invention describes a method for producing an NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and induces proliferation, IFN-γ production, and cytotoxic activity. The method involves culturing isolated CD14 positive cells in a medium containing an NKT cell ligand and GM-CSF, while being substantially free of IL-4. Additionally, the patent outlines a method for producing an NKT cell ligand-pulsed human CD14 positive cell line, emphasizing the importance of the culture medium composition.
Career Highlights
Throughout his career, Hanada has worked with notable organizations, including Riken Corporation and Ambicion Co., Ltd. His experience in these companies has contributed to his expertise in the field of cell biology and immunotherapy.
Collaborations
Hanada has collaborated with esteemed colleagues such as Masaru Taniguchi and Tomokuni Shigeura. These partnerships have fostered a collaborative environment that enhances research and innovation in the field.
Conclusion
Keigo Hanada's work in NKT cell activation technology represents a significant advancement in immunological research. His innovative methods and collaborations continue to influence the field and hold promise for future therapeutic applications.